FAST NEWS: CStone licenses PD-1 cancer drug to 3SBio for China
The latest: CStone Pharmaceuticals (2616.HK) announced Wednesday that it has exclusively licensed Shenyang Sunshine Pharmaceutical, a subsidiary of 3SBio Inc. (1530.HK), to develop, register, manufacture and commercialize its anti-PD-1 antibody Nofazinlimab…
2616.HK
FAST NEWS: CStone says CEO to boost company holdings
The latest: CStone Pharmaceuticals (2616.HK) on Tuesday announced that its CEO Jason Yang plans to buy up to HK$5 million ($640,000) worth of the company’s shares in the open market over the…
2616.HK
CStone breaks up with drugs partner as U.S. rollout stalls
CStone Pharmaceuticals has pulled out of a licensing deal with EQRx for two innovative cancer drugs but holds onto money already received from its partner Key Takeaways: The companies parted…
2616.HK
FAST NEWS: CStone Raises $50 Million in New Share Placement
The latest: CStone Pharmaceuticals (2616.HK) on Wednesday announced it placed 84.8 million new shares at a price of HK$4.633 per share, raising approximately HK$393 million ($50.4 million). The sale price…
FAST NEWS: CStone Revenue Doubles, Helping Company Pare Losses
The latest: CStone Pharmaceuticals (2616.HK) announced on Thursday it expects to report its revenue doubled to 475 million yuan ($70 million) or more last year, while its net loss narrowed…
Is Former CStone Chairman the Medicine Ailing Hengrui Needs?
Hengrui Medicine started the New Year by naming CStone’s previous top official Jiang Ningjun as its new vice general manager and chief strategy officer.Key Takeaways:Hengrui Pharma has named the former…
Surging Beigene Catches Case of Forex Flu
The drug maker’s net loss grew in the third quarter due to weakness in the Chinese yuan, even as its revenue nearly doubledKey Takeaways:Surging sales for its two self-developed drugs…
